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Background: Evidence from several recent metabolomic studies suggests that increased concentrations of
triacylglycerols with shorter (14–16 carbon atoms), saturated fatty acids are associated with insulin resistance and
the risk of type 2 diabetes. Although causality cannot be inferred from association studies, patients in whom the
primary cause of insulin resistance can be genetically defined offer unique opportunities to address this challenge.
Methods: We compared metabolite profiles in patients with congenital lipodystrophy or loss-of-function insulin
resistance (INSR gene) mutations with healthy controls.
Results: The absence of significant differences in triacylglycerol species in the INSR group suggest that changes
previously observed in epidemiological studies are not purely a consequence of insulin resistance. The presence of
triacylglycerols with lower carbon numbers and high saturation in patients with lipodystrophy suggests that these
metabolite changes may be associated with primary adipose tissue dysfunction. The observed pattern of triacylglycerol
species is indicative of increased de novo lipogenesis in the liver. To test this we investigated the distribution of these
triacylglycerols in lipoprotein fractions using size exclusion chromatography prior to mass spectrometry. This associated
these triacylglycerols with very low-density lipoprotein particles, and hence release of triacylglycerols into the blood
from the liver. To test further the hepatic origin of these triacylglycerols we induced de novo lipogenesis in the mouse,
comparing ob/ob and wild-type mice on a chow or high fat diet, confirming that de novo lipogenesis induced an
increase in relatively shorter, more saturated fatty acids.
Conclusions: Overall, these studies highlight hepatic de novo lipogenesis in the pathogenesis of metabolic
dyslipidaemia in states where energy intake exceeds the capacity of adipose tissue.Background
Insulin resistance (IR) is a major factor in the develop-
ment of type 2 diabetes mellitus (T2DM) and underpins
the tight relationships among obesity and many of its
metabolic complications, including hyperglycaemia, high
triacylglycerol (TAG) levels, low high-density lipopro-
tein (HDL)-cholesterol, non-alcoholic fatty liver disease
(NAFLD), and hypoadiponectinaemia as well as hyper-
androgenism in women. Although progress has been
made in understanding the molecular basis of human* Correspondence: jules.griffin@mrc-hnr.cam.ac.uk
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article, unless otherwise stated.IR, considerable uncertainty remains. Obesity is the
major association with the recent increase in IR inci-
dence, so understanding the mechanistic basis of this
association is a priority. Genetic susceptibility also plays
an important role, but results to date from population-
wide genetic studies, and the well-established hetero-
geneity seen even in the known Mendelian forms of
T2DM, argue that determining the nature of this is
likely to be very challenging.
Lipidomic profiling in epidemiological and cohort stud-
ies has recently suggested that both non-esterified fatty
acids and fatty acids covalently linked to glycerol in TAGs
tend to be shorter and more saturated, containing palmi-
tate and stearate, in insulin resistant people, and that the
TAG profile is another significant predictor of future
T2DM [1, 2]. More recently, Stegemann and colleaguesis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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relative risk of developing cardiovascular disease (CVD) in
the prospective population-based Bruneck study (685
individuals analysed at baseline in 2010). These results
were further confirmed in the UK Twin Registry [3]. More
generally, T2DM, CVD and metabolic diseases have been
associated with major remodelling of lipid profiles in
plasma, suggesting that either lipid classes or specific lipid
species could be used to monitor disease progression
and treatment efficacy [4–6]. In purely epidemiological
studies, however, the associations do not truly probe
the mechanisms responsible for the association of a
given lipid species with the risk of developing T2DM or
CVD. Furthermore, such approaches require relatively
large cohorts and place significant demands on the ana-
lytical approaches used to molecularly phenotype indi-
viduals. An alternative approach is to investigate the
phenotype of rare genotypes where the underlying causes
of IR can be discerned.
Mendelian randomization is increasingly used to ad-
dress this problem of causality in associations, both in
large epidemiological cohorts and in rarer monogenic
disorders. Critical to this is the unequivocal direct link
of a congenital genetic defect to a perturbation of the
putative primary phenomenon of interest, in this case
IR, without any direct effect on the associated trait be-
ing tested. If this condition holds, then demonstrating
association between the IR-causing genetic variant and
this second trait provides strong evidence that it is
caused by IR. We and others have previously employed
this strategy in efforts to understand the relationship
between mitochondrial dysfunction and IR [7, 8]. Here,
we report plasma lipidomic profiling results for a cohort
of patients with severe IR due to either congenital lipody-
strophy (LD), a state characterized by primary adipose
tissue dysfunction, or loss-of-function mutations in the
genes encoding the insulin receptor signalling pathway,
sometimes referred to as ‘insulin receptoropathies’ (INSR).
Thus, using these groups of rare inherited forms of IR,
one can examine molecular changes associated with LD,
and hence adipose tissue dysfunction, or molecular events
associated with INSR to examine the consequences of a
primary deficit in insulin signalling. Furthermore, molecu-
lar events that are common to both LD and INSR are pre-
sumably downstream of the genetic causes of both INSR
and LD. In this manner one can begin to deduce what is
upstream or downstream in terms of the causes of IR.
In the present study, the lipidomic profile of the INSR
group was largely normal, whereas that of the LD group
was associated with a relative increase in TAGs con-
taining shorter (14–18 carbon atom fatty acids) and
more saturated fatty acids. Furthermore, we show that
these TAGs are exported by the liver in very-low-
density lipoprotein (VLDL), and that similar changesare observed when de novo lipogenesis (DNL) is stimu-
lated in the mouse by increasing consumption of a diet
rich in carbohydrates. Finally, we suggest that the in-
crease in these TAGs in previously reported epidemi-
ology studies may be associated with increased DNL in
the liver, aggravating NAFLD and IR, prior to either the
development of T2DM or CVD.
Methods
Patient sample collection
Clinical studies were approved by the National Health
Service Research Ethics Committee UK. Each participant
provided written informed consent, and all studies were
conducted in accordance with the principles of the Dec-
laration of Helsinki.
Genetically characterised patients were identified as part
of a longstanding programme of research into genetic and
acquired forms of severe IR. Fasting blood samples were
obtained from patients with severe IR caused by either
loss-of-function mutations in the insulin signalling path-
way or congenital generalised or partial LD. Clinical and
biochemical features of these participants are summarized
in Table 1. Healthy control volunteers were recruited by
advertisement. All controls were non-smokers, without
any medical conditions likely to influence energy balance
and without a family history of diabetes. Participants were
admitted to the Wellcome Trust Clinical Research Facility
in Cambridge the night before sampling where they were
provided with an energy balance meal of standard macro-
nutrient composition at 6 p.m. They then fasted overnight
prior to blood sampling the following morning.
Mouse study of diet-induced DNL
Male ob/ob mice and their wild type (C57Bl/6J) were
housed in a temperature- and humidity-controlled facil-
ity, with a 12 h:12 h light–dark cycle and access to water
ad libitum. Mice (n = 10/age group/genotype) fed on a
regular chow diet (caloric content of 11.5 % fat, 26.9 %
protein, 61.6 % carbohydrate) were sacrificed at the age
of 4 months. A separate group of mice was switched to
a custom-produced high fat diet (caloric content of 55%
fat, 29% protein, 16% carbohydrate) at 12 weeks and
sacrificed at the age of 4 months. Blood plasma was
collected by cardiac bleed and liver tissue collected and
rapidly frozen post mortem. Blood plasma (15 μl) and
liver tissue (100 mg) were stored at −80 °C until further
analysis. All animal protocols were approved by the UK
Home Office.
Lipidomic analysis by Direct Infusion Mass Spectrometry
(DIMS)
All solvents used were of liquid crystallography (LC)-
mass spectrometry (MS) grade or better and ordered from
Sigma Aldrich (Gillingham, UK). All internal standards
Table 1 Characteristics of the healthy volunteers (controls) and patients with INSR mutations or LD
Controls Insulin receptoropathies Lipodystrophy P value
Gender 15 F, 12 M 6 F, 1 M 12 F, 2 M
Age (years) 39 ± 14 27 ± 11 36 ± 9 0.14
BMI (kg/m2) 24.6 ± 2.6 23.2 ± 3.6 24.1 ± 2.4 0.50
Fat mass (kg) 20.9 ± 8.5 22.6 ± 10.0 10.2 ± 5.0 <0.01
Lean mass (kg) 47.3 ± 10.8 34.2 ± 3.8 53.9 ± 10.7 <0.01
Glucose (mmol/l) 4.5 ± 0.5 4.7 ± 0.8 6.4 ± 2.7 <0.01
Insulin (pmol/l) 27 ± 20 419 ± 269 116 ± 65 <0.01
Adiponectin (mg/l) 6.4 ± 3.2 10.5 ± 7.9 2.9 ± 3.3 <0.01
Leptin (μg/l) 16.9 ± 22.1 16.1 ± 8.1 4.2 ± 3.0 0.24
Triglyceride (mmol/l) 0.9 ± 0.4 1.0 ± 0.3 2.9 ± 2.3 <0.01
HDL-cholesterol (mmol/l) 1.5 ± 0.4 1.8 ± 0.4 0.9 ± 0.5 <0.01
Data presented are mean ± standard deviation. BMI body mass index, F female, HDL high-density lipoprotein, M male
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tion of undecanoic acid and trilaurin (Sigma Aldrich,
Gillingham UK).
Human and mouse plasma samples (15 μl) were
extracted using an automated Anachem Flexus sample
preparation unit (Anachem, Milton Keynes, UK) to
minimize experimental variation. A total of 48 blood
plasma samples were included for the human study, with
the remaining positions of the 96-well plate occupied by
either blanks or quality control (QC) samples. The
samples, QC samples and blanks were placed in a pre-
defined random order across the 96-well plate. For the
QC samples, a pooled aliquot was created by mixing 10
μl of all samples to create the QC. Each plasma sample
was placed into 1.2 ml Cryovials for the Flexus to sam-
ple. To each vial 100 μl of MilliQ water was added and
thoroughly mixed. The solution (100 μl) was transferred
to a glass coated 2.4 ml deep well plate (Plate+, Esslab,
Hadleigh, UK). CH3OH (250 μl) was added containing six
internal standards (0.6 μM 1,2-di-o-octadecyl-sn-glycero-
3-phosphocoline, 1.2 μM 1,2-di-O-phytanyl-sn-glycero-3-
phosphoethanolamine, 0.6 μM C8-ceramide, 0.6 μM
N-heptadecanoyl-D-erythro-sphingosylphosporylcholine,
6.2 μM undecanoic acid, 0.6 μM trilaurin), and then 500
μl of methyl tert-butyl ether was added and mixed. The
plates were sealed using Corning aluminium microplate
sealing tape (Sigma Aldrich, UK) and shaken for 10 min at
600 rpm, after which the plate was transferred to a centri-
fuge and spun for 10 min at 6000 rpm. Each well in the
resulting plate had two layers, with an aqueous layer at
the bottom and a hydrophobic layer on top containing the
lipid extract. A 96-head micro-dispenser (Hydra Matrix,
Thermo Fisher Ltd, Hemel Hampstead, UK) was used to
transfer 25 μl of the hydrophobic layer to a glass-coated
25 μl low well plate (Plate+, Esslab, Hadleigh, UK) and
with 90 μl of 7.5 mM NH4Ac IPA:MeOH (2:1) using a
Hydra Matrix, after which the plate was sealed usingCorning aluminium microplate sealing tape (Sigma
Aldrich, UK) and stored at −20 °C until analysis.
Lipidomics was performed on the extract using chip-
based nanoelectrospray with an Advion TriVersa Nano-
mate (Advion, Ithaca, USA) interfaced to the Thermo
Exactive Orbitrap (Thermo Scientific, Hemel Hampstead,
UK), using a mass acquisition window from 200 to 2000
m/z and acquisition in positive and negative mode. The
Nanomate infusion mandrel was used to pierce the seal of
each well before analysis, after which a fresh tip was pre-
wetted by three repeat mixes of 6.5 μl of the sample and 5
μl was aspirated, followed by an air gap (1.5 μl). The tip
was pressed against a fresh nozzle and the sample was
dispensed using 0.3 psi nitrogen pressure. A voltage of 1.2
kV was used in positive mode and −1.5 kV in negative
mode with an acquisition time of 72 s in both modes and
a total analysis time of ~3 min per sample. The tip was
discarded and replaced for each sample to minimise sam-
ple carry-over. Throughout the acquisition the sample
plate was kept at 15 °C.
Acquired spectral raw data were processed using an
in-house bioinformatics platform based on XCMS [9].
This performed sample-specific mass re-calibration
using predefined sets of internal standards and the re-
moval of commonly present contaminant ions (often
associated with plasticizers) with help of predefined
rejection lists and mass defect filters. The raw data
were converted to .mzXML (using MSconvert [10] with
peakpick level 1), parsed with R and 50 (scan from 20
to 70) spectra were averaged per sample using XCMS
[9], with a signal cutoff at 2000. The files were aligned
using the XCMS [9, 11] grouping function using
“mzClust” with a m/z-window of 22 ppm and a mini-
mum coverage of 60 %, giving 1699 signals. Isotopes
were annotated using the CAMERA package in R with
the following parameters (maxcharge = 1, ppm = 5,
mzabs = 0.001, intval = c(“into”), minfrac = 0.25) [11].
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using both exact mass search in compound libraries as
well as applying the referenced Kendrick mass defect
approach. Features of interest were subsequently con-
firmed using fragmentation experiments on a Thermo
Velos Orbitrap mass analyser using an Advion Nanomate
to directly infuse the lipid extract. The selected masses
were isolated with a 1.5 m/z width in the linear ion trap
and then fragmented using either linear ion trap with 35%
relative collision energy or in the HCD (higher-energy
collision-induced dissociation) collision cell, with a range
of collision energies from 5% to 75% relative collision
energy. All spectra were recorded in the Orbitrap set at
100,000 resolution.
All human DIMS data have been deposited at the reposi-
tory MetaboLights [12] (accession number MTBLS162).
Size exclusion chromatography of human blood plasma
Freshly thawed plasma samples were diluted with
phosphate-buffered saline (PBS; 1 volume plasma:5 vol-
umes PBS). Lipoprotein particles were separated on a
Shimadzu Prominence UFLC system using a Superose
6 PC 3.2/30 column (GE Healthcare Europe GmbH,
Munich, Germany) with PBS as a mobile phase (at 50
μl min−1). The eluent was led to a Syrris FLLEX module
(Syrris, Royston, Herts, UK), which also received
CHCl3/MeOH (3:1) at 50 μl min
−1. Using a 250 μl loop
the two phases were mixed and then separated using a
Teflon membrane in the pressurized glass flow cham-
ber of the FLLEX module. This produced both the
aqueous and organic phases as separated eluents. The
organic phase was mixed with 1:1 isopropanol/metha-
nol containing 7.5 mM ammonium acetate at 150 μl
min−1 and led to a standard electrospray source on a
LTQ Orbitrap Velos for the acquisition of mass spectra.
RT-PCR of transcripts involved in de novo lipogenesis
Total RNA was extracted from 15 mg of mouse liver using
the RNeasy lipid tissue kit (Qiagen, Hilden, Germany)
following the manufacturer’s protocol, and the mRNA
diluted in RNase free water. The amount of RNA ex-
tracted was measured on a NanoDrop spectrophotometer
(Thermo Fisher Scientific, USA) and the purity of the
mRNA determined by measuring the A260/A280 ratio on a
spectrophotometer. mRNA was converted into cDNA
using the Quantitect reverse transcription kit (Qiagen,
Hilden, Germany) following the manufacturer’s guidelines.
cDNA was diluted in RNase-free water to 50 ng of cDNA
as a template for amplification. RT-PCR was carried out
using the TaqMan approach on a StepOnePlus instrument
(Applied Biosystems, USA). Reactions were loaded onto a
96-well plate for each gene tested. Each experiment was
carried out in duplicate, with each well containing the
primers for the amplification of the endogenous controlDNA (45S) and for the gene of interest. The amplification
for each test sample, non-template control, or pool sample
was performed in triplicate. Primers for RT-PCR were ob-
tained from Applied Biosystems. All data were normalized
to 18S rRNA and quantitative measures obtained using
the Δ-Δ-CT method.
Statistical analysis
Univariate analysis was performed within Prism 6.02
(Graphpad) and Excel (Microsoft, USA). Values were
compared using the Student’s t-test or ANOVA as
appropriate. For multiple comparisons the Bonferoni
correction was used and the significance level stated for
these comparisons (pi ≤ α/m, where α is the desired
familywise error, m is the number of tests performed
and pi is the corrected p value for individual tests). In
addition, multivariate statistics were used to visualise the
lipidomic changes simultaneously using latent variables
for the visualisation, including the multivariate approaches
of principal components analysis (PCA), partial least
squares discriminate analysis (PLS-DA) and orthogonal
two partial least squares discriminate analysis (O2PLS-
DA) [13, 14] within the SIMCA-P 13.0 software suite
(Umetrics, Umea, Sweden). For ease of interpretation,
O2PLS-DA plots are reported in the manuscript as these
maximise separation between two groups in the first com-
ponent, with the second component being generated
representing variation that is not associated with class
membership. Variables associated with this separation
were identified using the variable importance parameters
for the plot and the associated S-plots [13]. Model validity
was assessed by consulting the associated goodness of fit
of the model (Q2), along with the measures of CV-
ANOVA and sample prediction from within SIMCA
(Umetrics, Umea, Sweden) [15].
Results
Characteristics of the participants
Fasting plasma samples were collected from partici-
pants at the same time following a standardised even-
ing meal on the prior evening. The healthy control
group was age- and body mass index-matched to both
the seven patients with loss-of-function mutations in
the INSR gene (Table 1) and 14 patients with congeni-
tal LD (Table 1). Twelve of the patients with congenital
LD had familial partial LD due to either LMNA (lamin
A/C; n = 9) or PPARG (peroxisome proliferator acti-
vated receptor gamma; n = 3) mutations (Table 1). The
other two had congenital generalised LD. All patients
had acanthosis nigricans, a cutaneous marker of severe
IR, and the typical biochemical profile of patients with
either primary INSR defects (severe hyperinsulinaemia,
normal TAG and HDL-cholesterol levels, usually with
preserved or elevated serum adiponectin levels) or
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LD (severe hyperinsulinaemia, hypertriglyceridaemia,
low HDL-cholesterol, hypoadiponectinaemia and
hypoleptinaemia) (Table 1).
Comparison of the intact lipid fingerprint
We have previously described the strikingly different lipo-
protein profiles of patients with LD and INSR, with the
latter group being remarkably normal despite severe IR
[7]. As expected, VLDL levels were significantly increased
and HDL-cholesterol concentrations significantly reduced
in the LD group (Table 1). All samples were subjected to
liquid/liquid extraction and the organic phase was infused
directly into a benchtop orbitrap mass spectrometer, using
chip-based nanospray. Figure 1a depicts the mass region
between 300 and 900 m/z of two exemplary plasma lipid
profiles, acquired for one control and one LD individual,
and highlights what was detected in the overall group
analyses, with lower concentrations of sterol lipids and
cholesterol esters but significantly increased TAG con-
centrations in the LD group. In total, in positive ion
mode 25 diacylglycerides (LipidMaps classification
LMGL02), 40 triglycerides (LMGL03), 55 phosphocho-
lines (LMGP01), 51 phosphoserines (LMGP03), 9 phos-
phoinositols (LMGP06), 26 sphingomyelins (LMSP),
and 30 sterols (LMST) were potentially detected accord-
ing to a database search of the identified peaks across the
dataset. We used multivariate statistical methods to inves-
tigate the relative changes in the lipid fingerprint across all
patients in more detail. O2PLS-DA analysis was unable to
separate all three patient groups simultaneously, although
the LD group showed clear differences from the other two
groups (R2(X) = 49.5%; R2(Y) = 51.5%; Q2 = 35.8% for the
model; Fig. 1b). Two-way comparison confirmed the
significant differences between the controls and the LD
group (R2(X) = 45.6%; R2(Y) = 57.4%; Q2 = 52.6%;
Fig. 1c). This model passed cross-validation by CV-
ANOVA (p = 0.0000007) with the two groups readily
separated in terms of predicted Y value (Fig. 1d). The
five most discriminating ions in this global assessment
were free cholesterol (m/z = 369.351: C27H46-H2O+H
+;
higher in controls and derived from free cholesterol
and fragmented cholesterol esters), TAG(52:2) (m/z =
876.802: C55H102O6+NH4
+; increased in LD), CE(18:2)
(m/z = 666.618: C45H76O2+NH4
+; increased in controls),
TAG(52:3) (m/z = 874.786: C55H100O6+NH4
+; increased
in LD) and TAG(50:1) (m/z = 850.786: C53H100O6
+NH4
+; increased in LD). A similar discriminatory
model with higher statistical significance was produced
between the INSR and the LD group (R2(X) = 74.7%;
R2(Y) = 89.7%; Q2 = 62.8%) (Fig. 1e). While the model did
not pass cross-validation by CV-ANOVA (p = 0.07), the
two groups were readily separated in terms of predicted Y
value (control score = 0.83 ± 0.21; LD score = 0.31 ± 0.30;p = 7.9 × 10−8 for a significant difference between the
two scores) (Fig. 1f ). The comparison between the IR
and the control group produced the weakest two-group
comparison (Fig. 1g; R2(X) = 36.4%; R2(Y) = 63.8%; Q2 =
33.2%), but the model passed cross-validation by CV-
ANOVA (p = 0.02), and the two groups were partially sep-
arated by predicted Y values (control score = 0.92 ± 0.17;
LD score = 0.32 ± 0.32; p = 1.0 × 10−7; Fig. 1h). The five
most discriminating ions in this global assessment were
sphingomyelin SM(36:1) (m/z = 731.606: C41H83N2O6P
+H+; increased in INSR), SM(18:1/18:1) (m/z = 729.591:
C41H81N2O6P+H
+; increased in INSR), PC(36:4) (m/z =
782.569: C44H80NO8P+H
+; increased in INSR), lyso-
phosphocholine (increased in control) and an unidentified
peak (exact mass 827.699; increased in INSR). Similarly,
the LD and INSR groups could be readily separated by
O2PLS-DA (Figure S1 in Additional file 1).
Investigation of TAG pool changes
To further investigate the observed changes in TAGs we
performed a targeted analysis of relative changes within
the TAG pool. A total of 40 different TAG species were
detected in protonated, sodiated and ammoniated ionisa-
tion form and ranged from a total of 46 to 58 carbons in
the acyl chains and from a fully saturated state to a max-
imum of ten double bonds. In order to reveal relative
changes in TAG pool composition we normalised the in-
dividual TAG profile against the total TAG signal, result-
ing in relative proportions for each TAG ionisation
product.
O2PLS-DA analysis on all three phenotypes simultan-
eously failed to reliably separate them but once again the
LD group clustered separately from the other two
groups (R2(X) = 86.6%; R2(Y) = 33.5%; Q2 = 26.3%;
Fig. 2a). Subsequent two-way comparison demonstrated
separation of the LD and control groups (R2(X) = 77.8%;
R2(Y) = 64.1%; Q2 = 51.7%; Fig. 2b). Inspection of the
corresponding S-plots (Fig. 2c) revealed that TAG
species including TAG(50:1), TAG(48:1), TAG(48:0) and
TAG(46:1) were increased in LD patients whereas longer,
more unsaturated TAGs (including TAG(52:3), TAG(54:4)
and TAG(52:4)) were enriched in the control group. The
model passed cross-validation according to CV-ANOVA
(p = 0.001) and the two groups were separated according
to predicted Y (control score = 0.87 ± 0.19; LD score =
0.23 ± 0.29; p = 3.4 × 10−10; Fig. 2d). No model could be
built that discriminated the INSR group from controls
according to the TAG profiles (data not shown). However,
the LD and INSR groups were readily separated by
O2PLS-DA (R2(X) = 61.4%; R2(Y) = 63.4%; Q2 = 57.0%;
Fig. 2e). The model passed validation according to CV-
ANOVA (p = 0.006) and the two groups were readily
separated according to predicted Y (data not shown). The
separation was associated with increases in TAG(48:1),
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Fig. 1 Analysis of intact lipids in the blood plasma of individuals with lipodystrophy or insulin receptoropathies compared with matched controls.
a Two typical MS spectra from a control (in black) and an individual with lipodystrophy (in red, shown inverted). b O2PLS-DA analysis of the intact
lipid dataset for the control (CON), lipodystrophic (LD) and insulin receptoropathy (INSR) groups (48 individuals in total; controls = 27, LD = 14,
INSR = 7). The first two O2PLS-DA components are shown (R2(X) = 49.5%; R2(Y) = 51.5%; Q2 = 35.8%; two O2PLS-DA components were fitted).
c O2PLS-DA model of the control and LD groups. Note only one component is shown as this was the only component that passed validation
(the x-axis is arbitrary and the order applied is purely for ease of viewing; R2(X) = 45.6%; R2(Y) = 57.4%; Q2 = 52.6%; one O2PLS-DA component
fitted). d Predicted class membership of the two groups in (c). Control samples should score 1 and LD samples should score 0 in a perfect
model. e O2PLS-DA model of the INSR and LD groups. One O2PLS-DA component is shown alongside an orthogonal component (R2(X) = 74.7%;
R2(Y) = 89.7%; Q2 = 62.8%; one O2PLS-DA component and three orthogonal components fitted). f Predicted class membership for the model
in (e). LD samples should score 1 and INSR samples should score 0 in a perfect model. g O2PLS-DA model of the control and INSR groups.
One O2PLS-DA component and one orthogonal component is shown (R2(X) = 36.4%; R2(Y) = 63.8%; Q2 = 33.2%; one O2PLS-DA component
and one orthogonal component fitted). h Predicted class membership for the model in (g). Control samples should score 1 and INSR samples
should score 0 in a perfect model
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the LD group and increases in TAG(52:3), TAG(54:4),
TAG(54:5), TAG(52:4) and TAG(53:3) in the INSR
group as determined by the S-plot associated with the
O2PLS-DA plot (data not shown).To further investigate these TAG changes, univariate
analysis was performed on the dataset, comparing both
LD against controls and INSR against controls. While only
one triglyceride was significantly different in the INSR and
control group comparison (TAG(56:8) p = 0.0497, 16%
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Fig. 2 Analysis of the TAG component of the lipid profile from blood plasma of individuals with lipodystrophy or insulin receptoropathies compared
with matched controls. a O2PLS-DA analysis of the triglyceride dataset for the control (CON), lipodystrophic (LD) and insulin receptoropathy (INSR)
groups (48 individuals in total; controls = 27, LD = 14, INSR = 7). One O2PLS-DA component and one orthogonal component are shown
(R2(X) = 86.6%; R2(Y) = 33.5%; Q2 = 26.3%; one O2PLS-DA component and five orthogonal components fitted). b O2PLS-DA analysis of the
triglyceride dataset for the control and LD groups. One O2PLS-DA component and one orthogonal component are shown. (R2(X) = 77.8%;
R2(Y) = 64.1%; Q2 = 51.7%; one O2PLS-DA component and three orthogonal components fitted) c S-Plot of the O2-PLSDA analysis in (b)
showing the most discriminatory TAG species for the separation. d Predicted class membership for the model in (b). In a perfect model
control samples would score 1 and the LD samples score 0. e O2PLS-DA analysis of the triglyceride dataset for the LD and INSR groups. One
O2PLS-DA component and one orthogonal component are shown. (R2(X) = 61.4%; R2(Y) = 63.4%; Q2 = 57.0%; one O2PLS-DA component and
one orthogonal component fitted). f The relative distribution of triglycerides across the different lipoprotein fractions in human plasma, based
on size exclusion chromatography coupled to high resolution mass spectrometry using in-line automated liquid-liquid extraction. The cholersteryl ester
CE(18:2) (666.618 m/z ± 5 ppm) shows the distribution of the different lipoprotein fractions. Smaller saturated triglycerides [TAG(46:1) (794.721 m/z ± 5
ppm), TAG(48:1) (822.752 m/z ± 5 ppm) and TAG(50:1) (850.785 m/z ± 5 ppm)] are specific for the VLDL fraction coming from the liver, while larger
triglycerides [TAG(52:2) (876.800 m/z ± 5 ppm) and TAG(54:4) (900.800 m/z ± 5 ppm)] can also be found in the LDL fraction and therefore not only
originating from the liver
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17 TAG species were significantly different between the
LD and control groups. This was characterised by an in-
crease in TAGs containing relatively shorter but saturated
fatty acids in the LD group, along with a decrease in a
number of TAGs containing polyunsaturated fatty acids
(Fig. 3; Table S1 in Additional file 1).
The LD group was dominated by females, in keeping
with the ease in diagnosing the disorder in females com-
pared with males because of differences in body shape. To
ensure the changes in triglyceride profiles did not arise
from differences in the gender composition of the control,
LD and INSR groups we performed the same analysis on
just the females in the dataset. Applying O2PLS-DA tothe three groups, the LD group was found to be separ-
ate from the two other groups, although the model pa-
rameters were relatively poor (R2(X) = 36.1%; R2(Y) =
25.3%; Q2 = 19.5%; data not shown). However, building
a model for the LD and control groups readily discrimi-
nated the two, with this separation again caused by in-
creases in the concentrations of TAG(48:0), TAG(46:0),
TAG(48:1), and TAG(50:1) and relative decreases in
TAG(52:3), TAG(53:3), TAG(51:3), TAG(54:7) and TAG
(54:6) for the LD group (R2(X) = 50.8%; R2(Y) = 61.7%,
Q2 =30.5%; Figure S2 in Additional file 1).
To elucidate the fatty acid composition of the signifi-
cantly increased TAG species in LD patients we performed
fragmentation coupled to chromatographic analysis of the
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Fig. 3 Summary of triglyceride (TAG) changes for even numbers of carbons between the lipodystrophy (LD) and control groups. a Bubble plot of
fold changes for TAGs. Filled bubbles indicate an increase in concentration in the LD group, open bubbles a decrease in concentration. The area
of each bubble is proportional to the log2(fold change). b Bubble plot of p values for significance of change in a given TAG species between the
two groups (Student’s t-test). The area of the bubble is proportional to log10 of the p value. Filled bubbles indicate a significant increase, open
bubbles a significant decrease. Note only significant changes are shown as bubbles
Eiden et al. Genome Medicine  (2015) 7:63 Page 8 of 12lipid fraction using LC-MS/MS. This demonstrated that
the TAGs responsible for the discrimination of the LD
group contained palmitic and, to a lesser extent, myr-
istic acid (Table S1 in Additional file 1). In keeping
with these observations we also observed that TAGs
containing relatively short chain, saturated fatty acids
[TAG(46:1), TAG(48:1) and TAG(50:1)] were highly
enriched in the VLDL fraction, while TAGs with essential
fatty acids were also present in the LDL fraction. We
demonstrated this with the help of size exclusion chroma-
tography [16] coupled to high resolution MS using in-line
automated liquid-liquid extraction (Fig. 2f). TAGs
enriched in palmitic acid and myristic acid are consistent
with increased DNL of fatty acids from carbohydrates (for
a review of this subject please see [17]).
To further explore the impact DNL has on the TAG
profile, we examined blood plasma TAGs in 4-month-
old wild-type and ob/ob mice fed a high carbohydrate
(chow) or high fat diet. It has previously been shown
that DNL is very significantly increased in chow-fed ob/
ob mice [18, 19] and reduced in mice fed high fat diets.
DIMS detected 45 triglycerides, with both the total lipid
profile and the TAG complement readily discriminatingthe mice according to genotype and diet (R2(X) = 71.6%;
R2(Y) = 94.8%; Q2 = 89.2%; Fig. 4a). Comparing the two
chow diet groups, ob/ob mice were readily separated
from control animals using O2PLS-DA (R2(X) = 71.8%;
R2(Y) = 99.8%; Q2 = 96.4%; Fig. 4b). We observed that
TAG(50:1) was increased 2.1-fold in the ob/ob mice
compared with the wild type on a chow diet (p = 0.0002;
Fig. 4c), and, in general, TAGs containing shorter chain
and more saturated fatty acids were increased in the ob/
ob mice fed a carbohydrate diet (TAG(52:2), TAG(54:3),
TAG(56:3), TAG(50:1) and TAG(52:2) were increased in
ob/ob mice and TAG(52:5), TAG(52:4), TAG(54:7),
TAG(52:6) and TAG(56:8) were increased in the wild-type
mice). To confirm that these TAG changes were associ-
ated with increased DNL, the concentration of transcripts
of key enzymes in DNL were measured by RT-PCR
(Fig. 4d). The expression of fatty acid synthase, acetyl-
CoA carboxylase 1, sterol regulatory element binding
protein-1c, stearoyl-CoA desaturase 1 and glycerol-3-
phosphate acyltransferase were all significantly increased
(two-way ANOVA, p < 0.0001).
Given that a high fat diet suppresses DNL in the liver,
we next compared wild type mice on a high fat diet with
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Fig. 4 Triglyceride profiles of mouse models associated with de novo lipogenesis. a O2PLS-DA analysis of the triglyceride profile of blood plasma
from 4-month-old wild-type (wt) and ob/ob mice on either a chow or high fat diet (HFD). The first two OPLS-DA components are shown (n = 9
per group; R2(X) = 71.6%; R2(Y) = 94.8%; Q2 = 89.2%; three O2PLS-DA components and two orthogonal components were fitted). b O2PLS-DA
analysis of the triglyceride profile of blood plasma from wild-type and ob/ob mice on a chow diet. The first O2PLS-DA component and orthogonal
component are shown (R2(X) = 71.8%; R2(Y) = 99.8%; Q2 = 96.4%; one O2PLS-DA component and three orthogonal components were fitted). c Relative
intensity of blood plasma TAG(50:1) in 4-month-old wild-type and ob/ob mice under high fat diet (HFD) and chow diet (n = 9 for each group; 2.1-fold
in the ob/ob mice compared with the wild type on a chow diet (p = 0.0002)). d Increased expression of genes involved in DNL in the liver of ob/ob
mice compared with wild-type controls as measured by RT-PCR. Expression of DNL genes in liver from 4-month-old wild-type control mice
(n = 6) and ob/ob mice (n = 6). Data are represented as mean ± standard error of the mean and all data were normalized to 18S rRNA.
Two-way ANOVA, p < 0.0001. FASN fatty acid synthase, ACACA acetyl-CoA carboxylase 1, SREBP1F sterol regulatory element binding protein-1c, SCD1
stearoyl-coenzyme A desaturase 1, GPAM glycerol-3-phosphate acyltransferase, mitochondrial. e O2PLS-DA analysis of the triglyceride profile of blood
plasma from wild-type mice on a high fat diet (HFD; low de novo lipogenesis) and ob/ob mice on a chow diet (high de novo lipogenesis). f Relative
intensity of blood plasma TAG(50:1) in 4-month-old wild-type mice on a high fat diet and ob/ob mice on a chow diet (n = 9 for each group).
***p < 0.001 according to Student’s t-test
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be most raised. O2PLS-DA of the TAG profile pro-
duced a robust model that readily discriminated the
two groups (R2(X) = 63.9%; R2(Y) = 99.3%; Q2 = 98.1%;
Fig. 4e), and the model readily passed cross-validation
using CV-ANOVA (p = 7 × 10−12). The ob/ob chow
diet group was associated with increases in TAG(52:2),
TAG(54:3), TAG(50:2), TAG(50:1) and TAG(56:3), while
the wild-type chow diet group was associated with in-
creases in TAG(52:4), TAG(54:6), TAG(54:5), TAG(52:4)
and TAG(54:7). This separation was associated with a 4.2-
fold increase in TAG(50:1) in the ob/ob chow diet group
compared with the wild-type high fat diet group (Fig. 4f).Discussion
The relative enrichment in shorter chain saturated TAG
species observed in samples from the LD group is re-
markably similar to that recently shown to be associated
with IR in a large epidemiological study [1] and smaller
selected cohort studies [2, 20]. This pattern was also
observed in samples from five healthy men fed a hyper-
caloric carbohydrate-enriched diet specifically designed
to stimulate hepatic DNL [21]. These data are also con-
sistent with stable isotope-based measurements of the
rate of DNL in patients with LD and INSR mutations
[7]. In this previous study DNL was found to increase
over threefold in lipodystrophic individuals compared
Eiden et al. Genome Medicine  (2015) 7:63 Page 10 of 12with the control group, with those with insulin recep-
toropathies and mutations in AKT2 being intermediate
in terms of their DNL capacity. Although detailed
physiological measurements of the relative contribu-
tions of adipose tissue lipids, dietary lipids and DNL-
derived lipids to liver and plasma TAGs suggest that
lipolytically derived fatty acids constitute by far the
greatest source of lipids [22], our data imply that in-
creased DNL significantly changes the composition of
the triglycerides in lipodystrophic patients and probably
also in other prevalent forms of the metabolic syn-
drome. Furthermore, our assay used to measure triglyc-
erides associated with DNL in the present study took
only 3 min to perform and required only 15 μl of blood
plasma compared with a two day intervention study to
measure DNL using stable isotopes. This allowed us to
measure groups of much larger size than in [7], and
also demonstrate that increased DNL was something
specific to the LD group and not found in the INSR
group in our larger powered study. This suggests that
raised DNL is associated with increased glucose uptake
into the liver as a result of a failure of adipose tissue
uptake in LD patients, rather than a mechanism that
is associated with the downstream effects of IR (and
would be common to both LD and INSR patients).
To further investigate DNL we conducted an animal
study to directly manipulate DNL and investigate the
liver directly. We examined the effect of a chow diet,
relatively high in carbohydrates, on DNL compared
with a high fat diet that suppresses DNL in both wild-
type and ob/ob mice. The ob/ob mouse with its in-
creased appetite because of a lack of leptin would be
expected to provide a more extreme phenotype on
both diets compared with its wild-type control. We
were able to demonstrate transcriptionally that DNL is
markedly increased in ob/ob mice compared with wild
type on a chow diet as has been previously reported
[23], and this was associated with a relative increase in
TAGs containing shorter, more saturated fatty acids as
in the LD group. However, the lipidomic changes were
not directly recapitulated as in the mouse study a more
limited number of TAGs were detected compared with
humans. In our previous studies we have found that
mice have a more limited set of TAGs typically within
their blood plasma [24–27], which may reflect the
more limited diet mice receive as well as genetic differ-
ences between the species. One of the most discrimin-
atory lipids was TAG(50:1), with a fourfold difference
in this lipid species between the wild-type mice on a
high fat diet, which would be expected to have the
most suppressed DNL capability, and ob/ob mice on a
chow diet, which has the highest capacity for DNL in
this mouse study. Furthermore, although obese, ob/ob
mice still have functional adipose tissue and consumedcarbohydrate will be taken up by both adipose tissue
and the liver, reducing the impact of DNL on the blood
plasma lipidome.
Dyslipidaemia is a common feature of a number of
metabolic diseases and it is usual for total triglyceride
concentrations to be measured as part of patient as-
sessment. However, these results demonstrate that not
all triglycerides should be considered together and cer-
tain species may act as proxies for specific biological
processes, in particular those containing shorter, more
saturated fatty acids which may reflect DNL. The se-
lective increase in TAGs that contain shorter, more
saturated fatty acids has been found in a number of co-
hort studies examining both T2DM and CVD [1–3].
These studies, together with our current study, strongly
suggest that DNL may make a significant contribution
to the relative risk of developing metabolic diseases.
Furthermore, the measurement of individual TAG spe-
cies may be particularly appropriate to the application
of precision medicine for sufferers with aspects of the
metabolic syndrome. For example, while glucokinase
agonists have been shown to reduce hyperglycaemia
dramatically in type 2 diabetics, they are also associated
with NAFLD in a subset of patients. However, Dhanesha
and colleagues have demonstrated that NAFLD can be
reduced in db/db mice if a glucokinase agonist is co-
administered with exendin-4, a GLP-1 agonist [28]. Thus,
a lipidomic assay for flux through DNL could be used to
assess the use of glucokinase agonists either with or with-
out a GLP-1 agonist.
Recently, together with Forouhi and colleagues [29],
we examined the fatty acid content of phospholipids in
blood plasma by gas chromatography to examine the
association of specific fatty acids with relative risk of
developing T2DM across over 28,000 individuals in
EPIC-InterAct. We found that myristic, palmitic and
staeric acid were all associated with increased risk of
developing T2DM. In addition, we examined which
foods were associated with these fatty acids as reported
in food frequency questionnaires, with alcohol, potato
consumption, margarine and sugary drinks being most
associated with these saturated fatty acids. With the ex-
ception of margarine consumption, the other three
food substances are all associated with DNL, suggesting
that foods that promote DNL may be responsible for
increased risk of T2DM. This emphasizes the import-
ance of considering individual lipid species rather than
considering either all saturated fatty acids or all trigly-
ceride species together. It also raises concerns in terms
of the development of fatty liver disease in the general
population given the cumulative health advice over the
last ~40 years to reduce saturated fatty acid intake,
which in turn has led to an increase in sugar intake in
many diets.
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Plasma lipid profiling in patients with LD and INSR
mutations indicates that the relative enrichment of
shorter chain saturated TAG species associated with
human IR in previous studies is not purely a secondary
consequence of defective insulin action. Our observa-
tions related to changes in the lipid profile of patients
with LD are also consistent with the notion that this
lipidomic pattern is a useful marker of IR likely to
reflect increased hepatic DNL and that it can develop
as a consequence of adipose tissue dysfunction. The
increase in DNL is most likely to be occurring in the
liver given the reduced adiposity in LD, although our
own data do not specifically address the site of DNL.
These changes can be recapitulated in mouse models of
DNL, with the caveat that humans appear to produce a
wider range of TAGs in terms of both fatty acid chain
length and degree of unsaturation.
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